In November 2025, CMS issued a DMEPOS/Home Health Final Rule that featured plans for a new Competitive Bidding (CB) round for products including diabetes products including insulin pumps and continuous glucose monitors (CGMs), which have not previously been subject to bidding. The Rule further mandates these products will be furnished through a national remote-item delivery mail-order process, with fewer than ten companies selected as suppliers.

Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME), Co-Chairs of the Senate Diabetes Caucus, have introduced legislation aimed at protecting access to diabetes technologies by keeping these products out of the DMEPOS CB  Program for 5 years, giving policymakers more time to study the potential impacts of moving forward with a national, remote-delivery framework.

Diabetes stakeholders can build important early support for S. 4037, the DIABETES Act by sending a letter to their Senators asking them to co-sponsor the legislation.

You are encouraged to add your own story to the letter to reflect your experience working with patients who use insulin pumps and CGMs and how this legislation is needed to allow you to continue supporting these individuals and their families.

Find additional messaging and resources on the DIABETES Act and other legislative initiatives on our 2026 Advocacy Priorities page.  Thank you for your advocacy.